Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Authors:
- Melanie Urbanek-QuaingMUMelanie Urbanek-Quaing
- Yin-Han ChouYCYin-Han Chou
- Manoj Kumar GuptaMGManoj Kumar Gupta
- Katja SteppichKSKatja Steppich
- Birgit BremerBBBirgit Bremer
- Benjamin MaasoumyBMBenjamin Maasoumy
- Heiner WedemeyerHWHeiner Wedemeyer
- Cheng-Jian XuCXCheng-Jian Xu
- Anke R. M. KraftAKAnke R. M. Kraft
- Markus CornbergMCMarkus Cornberg
- 19 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (3) , 739-754
Abstract
Background and Aims: Chronic HBV infection exhausts HBV-specific T cells, develops epigenetic imprints that impair immune responses, and limits the effectiveness of immune checkpoint inhibitor monotherapy, such as anti–programmed cell death ligand-1 antibody (αPD-L1). This study aimed to determine whether the DNA methyltransferase inhibitor decitabine (DAC) could reverse these epigenetic imprints and enhance immune checkpoint inhibitor efficacy in restoring HBV-specific T cell responses. Approach and Results: We investigated HBV-specific T cell responses by 10-day in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection. PBMCs were stimulated with HBV core-specific overlapping peptide pools and HLA-A*02–restricted peptides, core18 and pol455. The immunomodulatory effect of the DAC/αPD-L1 combination was assessed by flow cytometry, and our analysis included clinical characteristics, ex vivo DNA methylation of PBMCs, and IFNγ plasma levels. Treatment with DAC/αPD-L1 enhanced HBV-specific CD4+ T cell responses in a significant proportion of 53 patients, albeit with some variability. This effect was independent of the HBcrAg levels. Ex vivo DNA methylation revealed hypermethylation of key genes, such as IFNG among DAC-responders versus non-responders, supported by altered ex vivo IFNγ plasma levels. Further analysis of HBV-specific CD8+ T cell responses in 22 HLA-A*02-positive patients indicated distinct response patterns between core18 and pol455 stimulation, with pol455-specific CD8+ T cells showing increased susceptibility to DAC/αPD-L1, surpassing the αPD-L1 monotherapy response. Conclusions: The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro, highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for chronic HBV infection.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- Immunological scars after cure of hepatitis C virus infection: Long‐HepC?Current Opinion in Immunology, 2023
- Reverse inflammaging: Long-term effects of HCV cure on biological ageJournal of Hepatology, 2022
- Towards eradication of HBV: Treatment approaches and status of clinical trialsCurrent Opinion in Pharmacology, 2021
- The Contribution of Epigenetics to Cancer ImmunotherapyTrends in Immunology, 2020
- Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡Journal of Hepatology, 2020
- Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot studyJournal of Hepatology, 2019
- Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis BJournal of Hepatology, 2018
- Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programmingCurrent Opinion in Virology, 2018
- De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell RejuvenationCell, 2017
- Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and DClinical Microbiology and Infection, 2015